Target intelligence / Profile preview

Herpesvirus entry mediator receptor (HVEM)

Target
HVEM
Molecular classification
Receptor, Member of the tumor necrosis factor receptor (TNFR) superfamily
01

Overview

Herpesvirus entry mediator (HVEM; TNFRSF14; CD270) is a type I transmembrane protein belonging to the tumor necrosis factor receptor superfamily. It serves as a crucial immune regulatory receptor, binding ligands such as LIGHT (TNFSF14), lymphotoxin-beta, and viral envelope proteins (herpesvirus glycoprotein D). HVEM mediates signal transduction that promotes T and B cell activation, enhances cytokine production, and regulates apoptosis and immune defense in both normal and disease contexts. HVEM’s interactions establish a critical checkpoint for lymphocyte proliferation, tissue architecture, and host defense, and dysregulation of this pathway has been implicated in a range of inflammatory, infectious, and malignant conditions. Targeting HVEM or its ligands is being pursued for disease intervention, but care must be exercised due to its wide-ranging roles in immune function

Other names
Herpesvirus entry mediatorTNFRSF14CD270LIGHT receptor
02

Mechanism of action

Antagonism of LIGHT binding (e.g., neutralizing antibodies to block LIGHT-HVEM interaction); Modulation of NF-κB signaling downstream of receptor activation

03

Biological functions

Signal transductionCo-stimulation of T and B cell activationRegulation of immune responses (innate and adaptive immunity)Apoptosis regulationLymphocyte trafficking and tissue architecture maintenance
04

Disease associations

Inflammation (autoimmune and barrier organ diseases, e.g., rheumatoid arthritis, inflammatory bowel disease, COVID-19 pneumonia)Cancer (modulates apoptosis and tumor cell survival)Infection (herpesvirus entry via HSV glycoprotein D binding to receptor)Other immune-mediated diseases
05

Safety considerations

Broad immunomodulatory role may lead to unwanted immunosuppression or activation (increased infection susceptibility, autoimmunity)Genetic variants in LIGHT or receptor can alter drug response or disease riskPotential for immune checkpoint interactions and dysregulation
06

Interacting drugs

Neutralizing antibodies (e.g., against ligand LIGHT/TNFSF14) investigated in research contexts
07

Biomarkers

Elevated soluble LIGHT and decoy receptor 3 (DcR3, TNFRSF6B) levels, especially in autoimmune disease (e.g., rheumatoid arthritis synovial fluid)HVEM and LIGHT expression levels may serve as biomarkers for immune activation or disease progression

Beyond the preview

Go deeper on Herpesvirus entry mediator receptor (HVEM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpesvirus entry mediator receptor (HVEM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call